Archive for November 2013
Developing an Effective Dialogue with the FDA
Moderating an informative conversation surrounding FDA procedures and communication, Emmett Cunningham, Summit Chairman, draws detailed responses from Wiley Chambers and Malvina Eydelman of the FDA. Focusing the discussion around common questions on how best to interact with the FDA, both formally and informally, Emmett helps deliver the specific answers attendees at the 5th Annual Ophthalmology…
Read MoreThe Ophthalmology Market – “A View from the Public Sector”
Jeffrey Hoffman, Managing Director and Head of West Coast Healthcare Investment Banking for JPMorgan, gladly addresses the audience at the 5th Annual Ophthalmology Innovation Summit with a promising outlook. Expanding on the rise of individual company risks, Jeffrey shares specific increases in the biotech and life sciences markets, as they recover from a 10-year lull.…
Read More2013 Ophthalmology Innovation Summit Innovator Awards
William J. Link PhD, Managing Director for Versant Ventures, announces the winners of the 2013 OIS Innovator Award. Describing the caliber and achievement that merits this award, Bill recognizes Thomas Burns, President & CEO for Glaukos, and Richard Hill MD, Co-Founder for Glaukos, for their high impact ophthalmic innovations that have successfully improved the lives…
Read MoreGoing Public – Who, When, and Why?
Detailing the grueling process and levels of determination necessary to go public, David Guyer, CEO for Ophthotech, begins this panel discussion with some of the more trying aspects of going public. Continuing to lead this distinguished panel through a IPO focused conversation, David stresses the importance of timing and perseverance throughout the planning and on…
Read MoreThe NEI Continues to Explore the Root Cause of Glaucoma
Ophthalmic Innovation 2013 – “A View from the NEI” Paul Sieving, Director for the National Eye Institute, leads the attendees at the 5th Annual Ophthalmology Innovation Summit @ AAO through a overview of the organizations goals and accomplishments. Sharing the institute’s focus on discovering the cause of Glaucoma, Paul continues to share highlights on the…
Read MoreSustained Ophthalmic Therapies Pave the Future for Ocular Therapeutix
Amarpreet Sawhney, President & CEO for Ocular Therapeutix, shares the company’s vision of becoming the leading developer of sustained ophthalmic therapies. Striving to improve patient outcomes, Amarpreet details the company’s proprietary technology that works across the front, back and surface of the eye. Presenter: Amar Sawhney, PhD Amarpreet Sawhney, Ph.D., co-founded Ocular Therapeautix in 2006,…
Read MoreNeurotech Transforms the Delivery of Biologics
Ted Danse, President & CEO for Neurotech, begins by touching upon their ETC technology platform, labeling it as “transformational” in its ability to deliver biologics over multiple years with one simple and minimally invasive procedure. Continuing to detail the key components of their program, Ted expands on the company’s progress thus far. Presenter: Edward (Ted)…
Read MoreALG1001 Leads Allegro’s Progress in Retinal Diseases
Vicken Karageozian, Co-Founder & CTO for Allegro Ophthalmics, shares his company’s story and highlights the progress of their lead molecule, ALG1001, a lead program for several retinal diseases. This program offers a long duration of effect, the option of using combination therapy and treatment for patients who have plateaued or are no longer responding to…
Read MoreAMAO76 Alleviates the Pressure for Amakem Therapeutics
Jack Elands, CEO for Amakem, talks about his company’s focus on a localized drug action platform, and details the company’s feature glaucoma product to lower intraocular pressure designated, AMAO76 rokinase inhibitor. Presenter: Jack Elands Dr. Jack Elands has been the CEO of Amakem since its inception. Before, Jack was CBO of Silicos, an informatics based…
Read MoreNew Injection Technology Sets the Standard for Icon BioSciences
William S. (Sandy) White, President & CEO for Icon BioSciences, discusses the company’s increasing portfolio of products that target most major therapeutic areas of ophthalmology. Stressing the importance of getting the correct drug, in the correct place, with the best clinical approach, Sandy details the progress of their latest products and briefly highlights their newest…
Read MoreNPP Meets the Mark for Kala Pharmaceuticals
[creativ_media type=”vimeo” url=”https://vimeo.com/82003104″] Guillaume Pfefer, President & CEO, shares Kala Pharmaceutical’s breakthrough technology Nucleolus Penetrating Particle with the audience of the 5th Annual Ophthalmology Innovation Summit. Detailing how this technology benefits a variety of conditions, Guillaume explains how the NPP can be leveraged to treat, post cataract surgery inflammation, dry eye, plethoritis and a demonstration…
Read MoreNovaliq Clears the Obstacles in Ocular Track Delivery
Bernhard Gunther, CEO for Novaliq GmbH, introduces their approach to improving topical ocular track delivery. Detailing the challenges involved, Bernhard expands on their unique opportunity to resolve these issues by dissolving poorly soluble tracks, with low viscosity and surface tension. Presenter: Bernhard Günther Bernhard Günther joined Novaliq as CEO in January 2007. He has more…
Read More